Department of Obstetrics and Gynecology, Columbia University, New York, NY (Drs Overton, Friedman, Azad, Nhan-Chang, Booker, Khoury-Collado, and Mourad).
Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, CA (Dr Wen).
Am J Obstet Gynecol MFM. 2023 Dec;5(12):101174. doi: 10.1016/j.ajogmf.2023.101174. Epub 2023 Oct 5.
Although peripartum hysterectomy for placenta accreta spectrum disorder is known to be associated with complications at the time of delivery, there are limited data on postpartum outcomes and readmission risk in this population.
This study aimed to analyze risks for adverse outcomes and postpartum readmissions in the setting of peripartum hysterectomy for placenta accreta spectrum disorder by severity of placenta accreta spectrum disorder subcategory.
Using the 2016-2020 Nationwide Readmissions Database, this retrospective cohort study identified peripartum hysterectomies with a diagnosis of placenta accreta spectrum disorder. The primary exposure was placenta accreta spectrum disorder, subcategorized as placenta accreta vs increta/percreta. The primary outcome was readmission rate and delivery complications. Complications evaluated included the following: (1) nontransfusion severe maternal morbidity (ntSMM), (2) venous thromboembolism, (3) reoperation, (4) intraoperative complications, (5) hemorrhage, (6) sepsis, and (7) surgical site complications. We additionally evaluated delivery hospitalization and readmission mean length of stay, and hospital costs. Unadjusted and adjusted logistic regression models were fit for outcomes adjusting for clinical, demographic, and hospital factors. The association measures were expressed as unadjusted and adjusted odds ratios with 95% confidence intervals.
Between 2016 and 2020, 7864 hysterectomies during a delivery hospitalization with a diagnosis of placenta accreta spectrum disorder were identified (66.5% with placenta accreta and 33.5% with placenta increta/percreta diagnoses). The overall 60-day all-cause readmission rate was 7.3%. Most readmissions (57.2%) occurred within 10 days of hospital discharge. Compared with peripartum hysterectomy with a diagnosis of placenta accreta, hysterectomies with placenta increta/percreta diagnoses carried significantly increased risk of 60-day readmission (adjusted odds ratio, 1.31; 95% confidence interval, 1.01-1.71), inpatient mortality (odds ratio, 13.23; 95% confidence interval, 3.35-52.30), nontransfusion severe maternal morbidity (adjusted odds ratio, 1.43; 95% confidence interval, 1.20-1.71), intraoperative complications (adjusted odds ratio, 2.31; 95% confidence interval, 1.93-2.77), and surgical site complications (adjusted odds ratio, 1.55; 95% confidence interval, 1.23-1.95). The median length of stay during delivery hospitalization was longer for placenta increta/percreta (5.8 days; 95% confidence interval, 5.4-6.1) than for placenta accreta (4.2 days; 95% confidence interval, 4.1-4.3; P<.05). In addition, delivery hospitalization costs were higher in cases of placenta increta/percreta (median, $30,686; 95% confidence interval, $28,922-$32,449) than placenta accreta (median, $21,321; 95% confidence interval, $20,480-$22,163).
Complication and readmission risks after peripartum hysterectomy with placenta accreta spectrum disorder are high. Compared with patients with placenta accreta, patients with placenta increta/percreta had increased risk for delivery and postoperative complications and postpartum readmission, and increased costs and length of stay.
尽管已知胎盘植入谱系疾病的围产期子宫切除术与分娩时的并发症有关,但在该人群中,关于产后结局和再入院风险的数据有限。
本研究旨在通过胎盘植入谱系疾病亚类的严重程度分析胎盘植入谱系疾病围产期子宫切除术后不良结局和产后再入院的风险。
使用 2016-2020 年全国再入院数据库,本回顾性队列研究确定了胎盘植入谱系疾病的围产期子宫切除术。主要暴露是胎盘植入谱系疾病,细分为胎盘植入与植入/穿透。主要结局是再入院率和分娩并发症。评估的并发症包括:(1)非输血严重产妇发病率(ntSMM),(2)静脉血栓栓塞,(3)再次手术,(4)术中并发症,(5)出血,(6)败血症,(7)手术部位并发症。我们还评估了分娩住院和再入院的平均住院时间和住院费用。未调整和调整后的逻辑回归模型用于调整临床、人口统计学和医院因素后的结局。关联度量表示为未调整和调整后的优势比,置信区间为 95%。
在 2016 年至 2020 年期间,在诊断为胎盘植入谱系疾病的分娩住院期间进行了 7864 例子宫切除术(66.5%为胎盘植入,33.5%为胎盘植入/穿透诊断)。总的 60 天全因再入院率为 7.3%。大多数再入院(57.2%)发生在出院后 10 天内。与胎盘植入的围产期子宫切除术相比,胎盘植入/穿透诊断的子宫切除术有显著更高的 60 天再入院风险(调整后的优势比,1.31;95%置信区间,1.01-1.71)、住院死亡率(比值比,13.23;95%置信区间,3.35-52.30)、非输血严重产妇发病率(调整后的优势比,1.43;95%置信区间,1.20-1.71)、术中并发症(调整后的优势比,2.31;95%置信区间,1.93-2.77)和手术部位并发症(调整后的优势比,1.55;95%置信区间,1.23-1.95)。胎盘植入/穿透的分娩住院期间中位住院时间较长(5.8 天;95%置信区间,5.4-6.1)比胎盘植入(4.2 天;95%置信区间,4.1-4.3;P<.05)。此外,胎盘植入/穿透的分娩住院费用中位数较高(30686 美元;95%置信区间,28922-32449)比胎盘植入(21321 美元;95%置信区间,20480-22163)。
胎盘植入谱系疾病围产期子宫切除术后的并发症和再入院风险较高。与胎盘植入患者相比,胎盘植入/穿透患者分娩和术后并发症及产后再入院风险增加,且费用和住院时间增加。